# A Study of Atezolizumab in Combination With Bevacizumab in Patients With EGFR Mutation Positive Stage IIIB-IV Non-Squamous Non-Small Cell Lung Cancer

> **NCT04426825** · PHASE2 · COMPLETED · sponsor: **Hoffmann-La Roche** · enrollment: 23 (actual)

## Conditions studied

- Carcinoma, Non-Small-Cell Lung

## Interventions

- **DRUG:** Atezolizumab
- **DRUG:** Bevacizumab

## Key facts

- **NCT ID:** NCT04426825
- **Lead sponsor:** Hoffmann-La Roche
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-09-09
- **Primary completion:** 2022-01-19
- **Final completion:** 2023-02-10
- **Target enrollment:** 23 (ACTUAL)
- **Last updated:** 2024-05-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04426825

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04426825, "A Study of Atezolizumab in Combination With Bevacizumab in Patients With EGFR Mutation Positive Stage IIIB-IV Non-Squamous Non-Small Cell Lung Cancer". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT04426825. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*